Up Therapeutics, LLC (UpTx) is a biotech company focused on improving the effectiveness of cancer therapies by targeting the Ubiquitin-Proteasome system. Using rational design, in vitro screening, testing, and in vivo animal studies, the company has discovered a promising novel lead compound,
Up284, which targets the RPN13 receptor for proteasome substrates. Up284 effectively kills various cancers in a cell culture system and in animal models with a promising safety profile. Up284 shows promising for treating cancers of various types, including ovarian, prostate, multiple myeloma, triple negative breast cancer, and glioblastoma.
Up284, which targets the RPN13 receptor for proteasome substrates. Up284 effectively kills various cancers in a cell culture system and in animal models with a promising safety profile. Up284 shows promising for treating cancers of various types, including ovarian, prostate, multiple myeloma, triple negative breast cancer, and glioblastoma.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
RPN13 inhibitor
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
